# Human red blood cells upend decades of animal-model science > Researchers at Northwestern Medicine have just published, in the journal Nature Genetics, findings that challenge decades of understanding about how human red - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Profile - Published: 2026-07-06 - Canonical URL: https://mad-max.co/en/article/les-globules-rouges-humains-bouleversent-des-decennies-de-science-animale ## Introduction: a discovery that puts the mouse back in its place ### A team that dared to question the animal model Researchers at **Northwestern Medicine** have just published, in the journal **Nature Genetics**, findings that challenge decades of understanding about how human **red blood cells** form. Their **study**, led by principal investigator **Peng Ji**, reveals that this process works differently in humans than generations of experiments on laboratory mice had suggested. This kind of result doesn't come around every day. Biomedical research has long relied on the mouse model as a stand-in for human biology, particularly in the **study** of **hematopoiesis**, the process by which blood cells form. Discovering a fundamental divergence at this level forces a reconsideration of part of the scientific structure built on that foundation. ### At the heart of the disagreement: erythroblastic islands At the center of this **discovery** are **erythroblastic islands**, microscopic structures in the **bone marrow** where red blood cells form. In mice, these islands are organized around a central cell, a **macrophage**, which acts as a kind of nurturing nest for developing cells. **Ji's** team found that in humans, this centered architecture does not appear in the same way. This structural difference is not a minor technical detail reserved for specialists. It touches the very understanding of how our **body** produces roughly two million new red blood cells every second, a vital **process** for transporting oxygen throughout the body. *This kind of **discovery** reminds me how much science advances by demolishing its own certainties. For decades, we extrapolated from rodents to humans without always checking whether the analogy actually held up.* ## Peng Ji, the scientist behind the challenge ### A career devoted to basic hematology **Peng Ji** runs a lab at the **Feinberg School of Medicine** at **Northwestern University**, where he has spent years studying the fundamental mechanisms of blood cell formation. His work belongs to a tradition of basic **research**, less publicized than spectacular clinical trials, but just as essential for understanding the biological foundations of human disease. This new **study** illustrates the value of patient basic research: no immediate commercial interest, no promise of a short-term miracle treatment, but the potential to profoundly transform scientific understanding of a biological process essential to human **life**. ### A methodology built on direct human tissue Unlike previous studies, largely based on mouse models, **Ji's** **team** directly examined human tissue to map the actual organization of erythroblastic islands. This methodological approach, more costly and complex to carry out than classic animal experimentation, revealed differences that would have remained invisible with a mouse-only approach. This methodological choice underscores a growing trend in contemporary biomedical **research**: the need to directly validate, on human tissue, mechanisms long presumed universal based solely on results obtained in animals. *There is something admirable about this methodological rigor. Rather than settling for the usual shortcuts, the **team** chose the harder but more scientifically honest path.* ## ICAM4 versus C1q: the molecule that changes everything ### ICAM4's unexpected role The **study** identifies the molecule **ICAM4** as playing a central role in the human organization of erythroblastic islands, unlike the complement protein **C1q**, which dominates the organization in mice. This molecular distinction might seem abstract at first glance, but it has concrete implications for research on human blood diseases. If the molecular mechanisms regulating red blood cell formation differ significantly between the two species, then treatments developed and tested solely on mouse **models** might not work the same way, or with the same effectiveness, in human patients. ### Implications for blood diseases This **discovery** opens new avenues for understanding diseases such as anemia, certain blood cancers, and bone marrow disorders. By better understanding how human red blood cells actually form, researchers hope to identify new therapeutic targets more precisely tailored to human biology rather than its mouse approximation. Patients with chronic hematological disorders could, over time, benefit from **treatments** redesigned in light of this improved understanding of specifically human blood-production mechanisms. *This is where basic science meets real medicine. A molecule with obscure initials today could become, ten years from now, the basis for a treatment that changes the **lives** of patients with **serious** blood **diseases**.* ## Why mice have long dominated research ### The practical advantages of the mouse model The heavy reliance on mice in biomedical **research** stems from solid pragmatic reasons: a fast breeding cycle, relatively low cost, a well-mapped genome, and the ability to make precise genetic modifications. These advantages made the mouse the premier model organism for more than a century of modern biological research. These practical advantages, however, do not guarantee perfect biological equivalence with **humans**. Each species evolved under its own environmental and physiological constraints, which can produce significant differences in biological processes once presumed universal among mammals. ### A welcome reminder for all of biomedical research This **study** adds to a growing list of cases where results obtained in mice did not translate perfectly to humans, in fields as varied as immunology, neurology, and now basic hematology. This finding does not invalidate the overall usefulness of the mouse model, but it calls for greater caution in directly interpreting animal results. For the scientific community, this kind of **discovery** strengthens the case for increased investment in research methods based directly on human tissue, despite their higher cost and complexity compared with traditional animal models. *I'm not throwing stones at decades of mouse research — it has saved countless lives. But this **study** is a reminder that we must constantly re-examine our scientific shortcuts, even the most established ones.* ## Bone marrow, a quiet but essential factory ### Two million red blood cells a second The human **body** constantly produces new red blood cells to replace those reaching the end of their **life**, about 120 days after they form. This constant turnover, estimated at roughly two million **cells** per second in a healthy adult, depends entirely on the proper functioning of the erythroblastic islands in the bone marrow. Any disruption to this process, whether from disease, an aggressive medical treatment like chemotherapy, or a **genetic** disorder, can lead to **severe** anemia or other serious hematological **complications** requiring urgent medical care. ### A remarkably precise biological system The precision with which the human **body** regulates this massive, continuous cell production reflects remarkable biological sophistication. Every step of the process, from the initial stem cell to the mature red blood cell, is regulated by a complex set of molecular **signals** that research continues to decode gradually, **study** after study. This new **discovery** about the human organization of erythroblastic islands adds one more, but significant, piece to this complex biological **puzzle** that human blood formation still represents today. *We sometimes forget just how many silent biological feats our **body** performs every second. Two million **cells** produced while you read this sentence — that's staggering when you really think about it.* ## Possible repercussions for existing treatments ### Rethinking certain research protocols This **discovery** could prompt **pharmaceutical** and academic labs to review certain research **protocols** currently based on mouse models for developing treatments against blood diseases. A methodological shift of this magnitude generally takes time to spread across the entire international scientific community. **Researchers** working on therapies that specifically target red blood cell formation mechanisms will likely need to factor in this distinction between human **ICAM4** and mouse **C1q** when designing future preclinical trials. ### A measured warning sign, not a wholesale reversal It would be an overstatement to conclude that all prior research based on mouse models must be rejected. Many fundamental biological mechanisms remain, in fact, conserved across species. But this **study** illustrates the need for systematic, case-by-case verification, rather than automatically generalizing animal results to human biology. This nuance is essential to avoid two opposite excesses: total rejection of the animal model, which remains indispensable for many medical advances, and blind confidence that ignores the very real limits of this experimental approach. *Real scientific wisdom is rarely found in extreme positions. Neither total rejection of the animal model nor blind trust in it — just rigorous verification, **study** after study, like the one just carried out by the Northwestern team.* ## Publication in Nature Genetics, a mark of rigor ### A demanding peer-review process The publication of this **study** in **Nature Genetics**, one of the most respected scientific journals in the world in the field of genetics, guarantees a high level of methodological rigor. The journal's peer-review process is known for its severity, which strengthens the credibility of the conclusions presented by **Peng Ji's** team. This **recognition** from a leading journal does not guarantee the absolute infallibility of the results, but it constitutes a significant **quality** filter that sets this **research** apart from the less rigorously vetted publications that sometimes circulate in today's scientific landscape. ### A reach beyond specialized circles Beyond specialized journals, this **discovery** was quickly picked up by science-popularization platforms like **MedicalXpress**, reflecting the **general public's** interest in this kind of basic advance, even when it does not immediately lead to a concrete clinical application. This wider reach helps raise broader public awareness of the fundamental mechanisms of the **human** **body**, while also giving credit to the often-overlooked work of basic-biology researchers, far from the spotlight usually reserved for advanced-phase clinical trials. *It's reassuring to see basic **research** get a bit of public visibility. It's too often overshadowed by **announcements** of miracle treatments, even though it forms the indispensable foundation of every future **medical** advance.* ## What this discovery does not yet allow us to claim ### No immediate treatment on the horizon It's important to temper the enthusiasm sparked by this **discovery**. No concrete clinical treatment follows immediately from it. This is a basic-research advance that will still need to clear many more hurdles, including further preclinical studies, before potentially leading to concrete therapeutic **applications** for patients. This long timeline, often misunderstood by the **general public**, characterizes nearly all basic discoveries in biology. The path from identifying a molecular **mechanism** to a treatment available in the clinic typically takes many years, sometimes decades. ### Questions that remain open The **study** also raises new questions that **Peng Ji's** team will need to explore in **future** research: to what extent does this structural difference affect the speed or **quality** of human red blood cell production? Are there individual variations in this cellular organization depending on the age or health status of the patients studied? These unresolved questions are a reminder that science rarely advances in decisive leaps, but rather through a gradual accumulation of knowledge, with each **study** opening as many new questions as it closes. *I find it reassuring, rather than frustrating, that this **study** leaves so many questions open. It's a sign of honest research, one that doesn't pretend to explain everything at once just to make headlines.* ## The American biomedical research ecosystem ### Northwestern, a recognized research hub **Northwestern University** and its **Feinberg School of Medicine** rank among the most active American academic institutions in basic biomedical research. This **discovery** adds to a long list of significant contributions by the institution to understanding fundamental human biological mechanisms. Funding for this kind of basic **research**, often less publicized than applied clinical research, depends largely on public and private grants specifically devoted to advancing basic scientific knowledge, without any immediate promise of commercial return. ### A model of international collaboration This kind of **study** also illustrates the importance of **international** scientific collaboration, where results obtained in an American lab are quickly shared, discussed, and potentially replicated by research teams around the world, accelerating the overall pace of scientific advances in hematology. This rapid spread of knowledge, made possible by modern standards of open **scientific** publication, contrasts sharply with the much slower pace of scientific information sharing that prevailed just a few decades ago. *This kind of open international **scientific** collaboration is, in my view, one of the rare fields where humanity still cooperates truly effectively, beyond the usual borders and geopolitical rivalries.* ## Explaining without betraying scientific complexity ### The delicate balance of medical popularization Making a **discovery** as technical as the distinction between human and mouse cellular organization of erythroblastic islands accessible represents a real challenge in science communication. It requires simplifying enough to make the subject understandable, without betraying the real complexity of the biological mechanisms involved. This tension between accessibility and **scientific** rigor defines all of contemporary science journalism, particularly at a time when **medical** misinformation spreads quickly on **social media**, making faithful, data-accurate popularization all the more essential. ### Why this kind of story deserves to be told Beyond its intrinsic scientific interest, this **discovery** deserves to be told because it concretely illustrates how the scientific method works: constant questioning of established **assumptions**, rigorous empirical verification, and the humble acceptance that even decades of scientific **consensus** can be revised in light of solid new data. It is this methodological humility, more than the **discovery** itself, that may be the most **valuable** **lesson** for the general, non-specialist public to take from this story. *If this story should leave us with a single **lesson**, it's this: real science is not afraid to contradict itself when the evidence demands it. That's its greatest strength, not its weakness.* ## The next steps in the research ### Toward studies on larger populations **Peng Ji's** team plans to expand its research to larger, more diverse human tissue **samples**, in order to confirm that the observed results hold true well beyond the initial sample studied. This larger-scale **validation** step is essential before the **scientific** community fully adopts this new model of human cellular organization. Collaborations with other laboratories specializing in hematology, across the United States and potentially internationally, could also help replicate and deepen these initial results in the coming years of **research**. ### A potential still largely untapped If the results are confirmed on a larger scale, this **discovery** could pave the way for new therapeutic **approaches** specifically targeting the **ICAM4** molecule to treat certain human blood disorders, a lead that likely would never have emerged without this fundamental challenge to the classic mouse model. The exact potential of this therapeutic lead remains largely to be explored, but it clearly illustrates how a seemingly abstract basic-research **discovery** can eventually lead to concrete medical **applications** years later. *This potential, still vague today, could become, within a decade, a major therapeutic lead. That's the often-invisible bet that basic research makes with every new **discovery** of this kind.* ## What this story reveals about contemporary science ### The need to fund basic research This **discovery** is a powerful reminder of the importance of continuing to fund basic research, even when it doesn't promise immediate clinical results. It is precisely this kind of patient, rigorous research that, over time, fuels the major medical advances that eventually benefit millions of patients around the world. At a time when basic-research **budgets** are sometimes cut or redirected toward **priorities** considered more immediately profitable, this story stands as a concrete argument for maintaining stable, predictable funding for this kind of long-term scientific work. ### An example of rigor worth celebrating publicly The profile of **Peng Ji** and his team also illustrates the importance of **publicly** recognizing scientists who devote their careers to this kind of quiet basic **research**, rather than reserving **media** attention solely for spectacular announcements of miracle treatments that are rarely confirmed afterward. This public **recognition**, even a modest one, helps encourage future generations of researchers to pursue demanding scientific **careers**, whose fruits are often harvested only **years**, even decades, after the initial work begins. *I sincerely hope that profiles like this one will inspire young **researchers** to commit to basic science, despite the lack of immediate **glory** that too often comes with it.* ## An echo across other fields of comparative biology ### Precedents in immunology and neurology This **discovery** is not isolated in the recent history of biomedical research. Similar gaps between mouse models and human biology have already been documented in immunology, particularly in the study of inflammatory responses, as well as in neurology, where certain brain circuits show notable architectural differences between the two species. These precedents reinforce the significance of **Peng Ji's** **discovery**: it fits within a broader trend in modern biomedical research, which is gradually rediscovering the limits of the mouse model across several disciplines at once, forcing a global methodological reassessment. ### Toward medicine that is more faithfully human This trend feeds a broader movement in contemporary biomedical **research**, encouraging the development of alternative **technologies** such as human organoids or microfluidic chips that reproduce human tissue, in order to reduce exclusive reliance on animal models for **validating** fundamental biological mechanisms. These new **approaches**, still costly and complex at scale, could eventually complement, without necessarily fully replacing, the traditional use of animal models in basic biomedical **research** in the coming decades. *We may be witnessing a quiet but profound methodological turning point across all of biomedical **research**. It's not as flashy as a vaccine announcement, but it may be just as important in the **long run**.* ## What the public should take away, without overstating its reach ### Distinguishing basic discovery from therapeutic promise It is essential for the general public to clearly distinguish between a basic-research **discovery**, like the one presented here, and an imminent therapeutic promise. **Media** outlets specializing in science communication bear a particular **responsibility** to avoid creating false hope among patients with serious blood diseases who are waiting for concrete treatments. This distinction, often blurred in mainstream **media** **coverage** of scientific advances, deserves to be reiterated systematically, particularly for discoveries as technical as this one concerning the **cellular** organization of human erythroblastic islands. ### A scientific curiosity worth cultivating Beyond its potential medical applications, this **discovery** deserves to be shared simply because it nourishes the **general public's** scientific curiosity about how their own **body** works. Understanding how our red blood cells form, even without an immediate clinical application, enriches our collective scientific culture. This kind of curiosity, cultivated from a **young age** through quality **scientific** communication, also represents a long-term investment in training future generations of researchers who will carry on this kind of essential basic work. *I deeply believe in the value of this **curiosity** for its own sake, with no immediate application. It's often this, more than the promise of profit, that has historically led to humanity's greatest scientific advances.* ## Conclusion: a welcome lesson in scientific humility ### What we take away from this discovery This study from **Northwestern Medicine**, published in **Nature Genetics**, powerfully illustrates science's ability to correct itself when solid new data demand it. The **discovered** distinction between the organization of erythroblastic islands in humans and in mice does not undermine the overall usefulness of animal research, but it does highlight the need for direct human verification of the most fundamental mechanisms of the human **body**. ### Measured hope for the future of hematology Without promising an immediate miracle treatment, this **discovery** opens real possibilities for better understanding, and perhaps one day better treating, the blood diseases that affect millions of patients around the world. It is this kind of patient, methodical, rigorously verified advance that, year after year, drives lasting progress in medicine. *I'll close this **profile** with a simple conviction: science that truly advances is not the science that shouts the loudest, but the one willing to correct itself, patiently, as often as necessary.* **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - MedicalXpress — Discovery on human red blood cell formation, July 3, 2026 - Feinberg School of Medicine, Northwestern University — Research news ### Secondary sources - Nature — Genetics, peer-reviewed scientific publications - News-Medical.net — Medical research news - EurekAlert — Science and health news - ScienceDaily — Neurology and biology news --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/les-globules-rouges-humains-bouleversent-des-decennies-de-science-animale